通过C反应蛋白测量，中度至重度化脓性汗腺炎的安慰剂反应者炎症水平下降：两项双盲随机对照试验的事后分析 - Suppr

Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials.

作者信息

Gunter Simon J, Porter Martina L, Kimball Alexa B

机构信息

Harvard Medical School, Boston, Massachusetts.

Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

出版信息

Int J Womens Dermatol. 2024 Aug 21;10(3):e171. doi: 10.1097/JW9.0000000000000171. eCollection 2024 Oct.

DOI:10.1097/JW9.0000000000000171

PMID:39170879

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11338249/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c5e/11338249/4fa8a679e9c1/jw9-10-e171-g001.jpg

相似文献

Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials.通过C反应蛋白测量，中度至重度化脓性汗腺炎的安慰剂反应者炎症水平下降：两项双盲随机对照试验的事后分析

Int J Womens Dermatol. 2024 Aug 21;10(3):e171. doi: 10.1097/JW9.0000000000000171. eCollection 2024 Oct.

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.比美吉珠单抗治疗中重度化脓性汗腺炎患者的疗效和安全性（BE HEARD I 和 BE HEARD II）：两项为期 48 周、随机、双盲、安慰剂对照、多中心 3 期临床试验。

Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22.

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.阿达木单抗在中重度化脓性汗腺炎中的中期剂量策略：来自 III 期随机安慰剂对照 PIONEER 试验的综合结果。

Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.

Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.一项2期随机双盲研究安慰剂对照部分中阿达木单抗治疗中重度化脓性汗腺炎女性患者的研究

J Drugs Dermatol. 2016 Oct 1;15(10):1192-1196.

Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.基于既往生物制剂暴露情况的中重度化脓性汗腺炎患者使用司库奇尤单抗：来自 III 期 SUNSHINE 和 SUNRISE 研究的疗效和安全性分析。

Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098.

Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.热休克蛋白90抑制剂RGRN-305治疗化脓性汗腺炎的疗效与安全性：一项平行设计双盲试验

JAMA Dermatol. 2024 Jan 1;160(1):63-70. doi: 10.1001/jamadermatol.2023.4800.

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.比美吉珠单抗治疗中重度化脓性汗腺炎的疗效和安全性：一项 2 期、双盲、安慰剂对照随机临床试验。

JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905.

Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.化脓性汗腺炎研究者全球评估量表的验证：一种新型化脓性汗腺炎特异性研究者全球评估量表，用于干预性试验。

JAMA Dermatol. 2023 Jun 1;159(6):606-612. doi: 10.1001/jamadermatol.2023.0797.

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.实现化脓性汗腺炎应答评分与临床和患者报告结局的显著改善相关：来自 PIONEER I 和 II 的汇总数据的事后分析。

Acta Derm Venereol. 2018 Nov 5;98(10):932-937. doi: 10.2340/00015555-3012.

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.临床缓解率、安慰剂缓解率和显著相关的协变量取决于化脓性汗腺炎的结局测量选择：PIONEER 1 和 2 个体患者数据的事后分析。

J Am Acad Dermatol. 2020 May;82(5):1150-1157. doi: 10.1016/j.jaad.2019.12.044. Epub 2019 Dec 24.

本文引用的文献

Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design.量化未经治疗的化脓性汗腺炎患者皮损计数随时间的自然变化：对疗效指标和试验设计的意义。

JAAD Int. 2020 Nov 7;1(2):208-221. doi: 10.1016/j.jdin.2020.09.005. eCollection 2020 Dec.

High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?临床试验中高安慰剂率：问题在于评分系统还是药物疗效？

J Am Acad Dermatol. 2020 Dec;83(6):e431. doi: 10.1016/j.jaad.2020.07.040. Epub 2020 Jul 17.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.阿达木单抗治疗化脓性汗腺炎的两项 3 期临床试验。

N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答（HiSCR）作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。

Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献